Andrew McCandlish, PhD is an experienced leader within corporate/business development and operations across biotechnology, pharmaceuticals, and medical devices/diagnostics. In his current role as Chief Operating Officer at Revagenix, Dr. McCandlish is accountable for all business areas outside of R&D, including finance/accounting, corporate development, legal, and alliance management, where he has worked with the executive team to launch the company and secure venture capital and non-dilutive funding. Previously as Head of US Business Development at pH Pharma, he was responsible for partnering efforts (out/inlicensing, R&D collaborations) for oncology, NASH, and rare disease programs, and as acting VP of Business Development at Meissa Vaccines he negotiated licenses for vaccine candidates and supported the company’s Series A financing. At Achaogen, in addition to multiple roles within business development, Andrew led efforts to secure federal grant and contract funding and either secured or supported alliance management of approximately $350 million of non-dilutive funding. He also had operational responsibilities as Project Team Leader for a 14-member cross-functional team developing a therapeutic drug monitoring (TDM) assay successfully deployed in a critical Phase 3 trial, and partnering efforts to commercialize the TDM assay globally. Dr. McCandlish has led and supported efforts to fund multiple biotech and diagnostics companies through private investments, including a successful Series A at Revagenix, and authoring sections of S1/S3s in support of an IPO and follow-on financings, and raised funding from venture capital firms and angel investors. Andrew holds a PhD in Molecular Biology from Princeton University, where he studied outer membrane biogenesis in Escherichia coli in the laboratory of Thomas J. Silhavy, and a BS with Honors from The Ohio State University in Molecular Genetics/Business Marketing (Capital Program).